Comorbid bronchial asthma associated with higher risk for early-onset, severe, or prolonged alopecia areata

Significantly higher risk seen for rheumatoid arthritis and psoriasis

The most reported signs were erythema, desquamation, dryness, and oozing affecting the face, neck, and upper extremities

Significant difference seen at week 36 for total VASI score in baricitinib plus UV-B versus placebo plus UV-B groups

Darker skin phototypes and cigarette smoking were also associated with reduced melanoma risk

Increased odds of atherosclerotic cardiovascular disease seen in association with CLE and SLE, but not psoriasis

Tool demonstrated generalizability through high predictive performance in international clinical cohort

Differences in age at diagnosis, Breslow thickness, ulceration, mitoses, and site account for 86.5 percent of effect of sex on survival

Higher cumulative dose also linked to reduced rate of isotretinoin retrial in patients with acne aged 12 years or older

In this recurring column, Dermsquared and J.P. Morgan provide tailored financial strategies and investment insights for the dermatology community. Each 500-word article highlights key...

Significantly lower risk for SCC seen in univariable and multivariable analyses, but not in African American patients

Ritlecitinib alone or with narrow-band UVB phototherapy well tolerated and beneficial in nonsegmental vitiligo

Interest in cosmetic procedures significantly predicted by frequent self-viewing behavior

In study, authors describe only two cases of local recurrence among 148 tumors managed by watchful waiting after clinical resolution

Efficacy and safety for scalp psoriasis, seen at week 16, are maintained through week 52

More localized VLD seen in study cohort; 140 of 200 patients had less than 10 percent of body surface area affected

Increased risk seen in association with nine primary cancers, with highest risk at one to five years after diagnosis of primary cancer

CLICK HERE to watch Dr James Del Rosso give his expert clinical insights on VTAMA for atopic dermatitis

Additionally, interim analysis shows that the antiviral is safe but has no effect on pain among adults with mild-to-moderate clade II mpox 

CLICK HERE to watch Dr James Del Rosso’s dermatologic deep dive on Bimzelx (bimekizumab) for psoriatic arthritis

The nonsteroidal topical treatment is approved for patients 2 years and older

The monoclonal antibody treatment is for patients ages 12 years and older

CLICK HERE to watch Dr James Del Rosso provide an in-depth overview of Nemluvio (nemolizumab) for atopic dermatitis